Member Info for MrRSoul

Based on the projected 2026 landscape of top global pharmaceutical companies—characterized by high R&D spending, a focus on immunology/autoimmune diseases, and the need to replace revenue from patent expirations—

AbbVie,

Johnson & Johnson

GSK are the most likely candidates to be interested in ImmuPharma's P140 (Lupuzor™) platform in 2026

CSPC Pharmaceuticals (that is)

SYN00GOLD

You would expect their share chart to paint a better picture as a result of those facts wouldn't you?

Xviolet

Possible typo... maybe....'except' this one?

Pebsi

Yep totally agree.

Just clarify that your comment 'lets face it you have nothing better to do except argue whether "tim's a liar, tims not a liar"? that you were speaking in general terms (as it does not apply to me).

NettlesTheCat

My sentiments exactly!

Pebsi.

I for one would be interested to hear your prediction/forecast,

Loadsof....

Medication time !

4.9

Whats in the box?

Shirley

Gourd

That makes a lot of sense to me. But....... be prepared for contradictary comments from some posters on here who just can't help themselves.

Patience is the key.Oh and 'keep the faith'.

4.8

GLA

Looks like we continue to tread water until some relevant news is released. No change there then!

Keep the faith

Still early days imo to go jumping to conclusions.

'Don't Panic Captain Mainwearing'

Spantrout

Perhaps he is quietly confident that there will be no need to.

Positive thinking I know early days imo.Have faith. lol

Based on the current 2026 agenda and speaker list for the Financial Times US Pharma and Biotech Summit (May 14, 2026), there is no evidence that representatives from ImmuPharma are attending or speaking.

Financial Times

Financial Times

+2

Summit Details: The US Pharma and Biotech Summit is scheduled for May 14, 2026, at Convene at One Liberty Plaza in New York City.

ImmuPharma Activities: Recent updates from March 2026 indicate that senior management (Tim McCarthy, Dr. Sebastien Goudreau, and Dr. Tim Franklin) were focused on a 20 March 2026, "Investor Meet Company" presentation and internal P140 licensing negotiations.

Conflicting Events: While ImmuPharma is actively seeking a 2026 licensing deal for their P140 program, they are not listed among the speakers or participants for the FT event.

Good afternoon OTM.

You asked me a question (£6.5m? Where did you get that figure from? More like £2-3m imo).

Are you satisfied with my answer to you?

Yahoo Finance 9.4.2026.

https://uk.finance.yahoo.com/news/immupharma-p140-partnering-discussions-continue-063000153.html

The combined £6.5 million fundraise also provides capital to advance ImmuPharma's second key asset, Kapiglucagon, a treatment candidate for type 1 diabetes and thats what its all about!